Compare NVAX & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | ACHC |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1995 | N/A |
| Metric | NVAX | ACHC |
|---|---|---|
| Price | $6.58 | $14.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $10.78 | ★ $24.38 |
| AVG Volume (30 Days) | ★ 3.5M | 3.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.07 | 1.18 |
| Revenue | $1,064,651,000.00 | ★ $3,265,548,000.00 |
| Revenue This Year | $58.91 | $6.50 |
| Revenue Next Year | N/A | $4.38 |
| P/E Ratio | ★ $3.17 | $12.11 |
| Revenue Growth | ★ 20.27 | 4.58 |
| 52 Week Low | $5.01 | $12.63 |
| 52 Week High | $11.55 | $47.08 |
| Indicator | NVAX | ACHC |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 34.32 |
| Support Level | $6.43 | $13.60 |
| Resistance Level | $6.84 | $14.70 |
| Average True Range (ATR) | 0.21 | 0.95 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 23.95 | 32.02 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.